The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing BCMA- & GPRC5D- targeted therapies outside specialist centers: unmet educational needs
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, emphasizes the need to educate community hematologists on managing and preventing toxicity associated with BCMA- and GPRC5D-targeted therapies in myeloma treatment to ensure safe use in non-academic and community centers. Dr Zamagni highlights the need for a roadmap and educational activities at the local level to support the successful implementation of these therapies. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
